Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM

Sponsor

GlaxoSmithKline (Industry)

Overall Status

Completed

CT.gov ID

NCT01648153

Collaborator

(none)

Enrollment

Locations

Arms

Duration (Months)

2.6

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

GSK1070806 is a humanised IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). The aims of this placebo controlled study are to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1070806 in obese subjects with Type 2 diabetes mellitus (T2DM), and to gain a better understanding of the mechanism by which GSK1070806 exerts its therapeutic effects.

Condition or Disease	Intervention/Treatment	Phase
Diabetes Mellitus	Biological: GSK1070806 Other: Placebo (saline) Biological: GSK1070806	Phase 2

Detailed Description

The study will be a randomised, single-blind (sponsor-unblinded), placebo-controlled, study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of repeat intravenous infusions (2 doses 4-weeks apart) of GSK1070806 in obese patients with T2DM. The primary objective of the study will be to assess improvements in fasting and postprandial glucose control. This will be a parallel-group study in 30 obese subjects with T2DM who are poorly controlled on metformin monotherapy (HbA1C>7% but <9.5%), and who have levels of microalbuminuria indicative of progressive kidney disease i.e. 30-300mg/L albumin in urine or ACR ≥3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤30mg/mmol. There will be three treatment groups comprising two active and one placebo arm with 10 subjects per dose group. The study contains a broad range of biomarker assessments, the purpose of which is to evaluate the mechanistic basis by which GSK1070806 exerts its therapeutic benefit in subjects with T2DM.

Subjects will be randomised into one of the three treatment groups where they will receive two intravenous infusions of GSK1070806 or placebo twenty-eight days apart. A MMT challenge will be conducted on Day 1, Day 29, Day 57 and Day 85 for evaluation of the primary endpoints.

Study Design

Study Type:

Interventional

Actual Enrollment :

37 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Investigator)

Primary Purpose:

Basic Science

Official Title:

A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects With T2DM.

Study Start Date :

Aug 1, 2012

Actual Primary Completion Date :

Sep 1, 2013

Actual Study Completion Date :

Jan 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: GSK1070806 0.25mg/kg TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart	Biological: GSK1070806 To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
Active Comparator: GSK1070806 5mg/kg Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart	Biological: GSK1070806 To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
Placebo Comparator: Placebo (Saline) Two IV administrations of saline 4 weeks apart	Other: Placebo (saline) To compare the efficacy and biomarker changes between placebo and active groups

Arm

Intervention/Treatment

Active Comparator: GSK1070806 0.25mg/kg

TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart

Biological: GSK1070806

To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration

Active Comparator: GSK1070806 5mg/kg

Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart

Biological: GSK1070806

To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration

Placebo Comparator: Placebo (Saline)

Two IV administrations of saline 4 weeks apart

Other: Placebo (saline)

To compare the efficacy and biomarker changes between placebo and active groups

Outcome Measures

Primary Outcome Measures

Change from baseline in fasting plasma glucose and weighted mean glucose AUC (0-4hrs) post-Mixed Meal Test (MMT) [Up to 85 days after the first does]
To evaluate the efficacy of two repeat intravenous dose administrations of GSK1070806 in subjects with T2DM

Secondary Outcome Measures

Safety and tolerability parameters include: adverse events, clinical laboratory tests, electrocardiograms (ECGs), and vital signs [Up to 210 days after the first dose]
To evaluate the safety and tolerability of two repeat intravenous dose administrations of GSK1070806 in obese subjects with T2DM
Change from baseline in % HbA1c, fasting blood insulin, and C-peptide levels; change from baseline in weighted mean insulin, and C-peptide levels [AUC (0-4hrs)] post-MMT and derived measures of insulin sensitive [Up to 85 days after the first dose]
To evaluate the effect of two repeat intravenous dose administrations of GSK1070806 on additional markers of efficacy, in obese subjects with T2DM
AUC(0-τ) [Up to 210 days after the first dose]
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
Serum levels of free IL-18 and drug bound IL 18 [Up to 210 days after the first dose]
To investigate the effect of repeat intravenous doses of GSK1070806 on free and drug bound IL 18 levels (if measurable) in obese subjects with T2DM.
Change from baseline in serum and/or plasma levels of biomarkers of inflammation (e.g. hs-CRP, and IL-6) and metabolic disease (e.g. adiponectin, fructosamine, total cholesterol, high-density lipoprotein (HDL)/low-density lipoprotein (LDL), triglycerides [Up to 85 days after the first dose]
To explore the pharmacodynamic (PD) effect of repeat intravenous doses of GSK1070806 on biomarkers of inflammation and metabolic disease
Change from baseline in waist circumference and BMI [Up to 85 days after the first dose]
To investigate the effect of repeat intravenous doses of GSK1070806 on body composition in obese subjects with T2DM
Cmax [Up to 210 days after the first dose]
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
Tmax [Up to 210 days after the first dose]
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
after the second dose λz [Up to 210 days after the first dose]
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
t1/2 [Up to 210 days after the first dose]
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

A diagnosis of T2DM as determined by a responsible physician based on a medical evaluation including medical history, physical examination, and laboratory tests, with onset at least 6 months prior to Screening.
Male or female between 18 and 70 years of age inclusive, at the time of signing the informed consent.
HbA1c levels ≥ 7.0 % and ≤ 9.5%; at Screening.
On a stable dose of monotherapy with metformin for three months prior to screening, and at a total daily dose greater than or equal to 1000 mg for at least 2 months prior to dosing.
Fasting plasma glucose level < 13.3 mmol/L (240 mg/dL) at screening.
Obese with BMI ≥ 30 kg/m2, and < 40 kg/m2.
Presence of microalbuminuria: 30-300mg/L albumin in urine or Albumin Creatinine Ratio (ACR) ≥ 3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤ 30 mg/mmol (female and male)..
The subject is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
A female subject is eligible to participate if she is of:

Non-childbearing potential
Child-bearing potential and agrees to use an acceptable form of contraception.

Male subjects must agree to use one of the contraception methods listed
ALT < 2xULN; alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
Single or Average QTc, QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.

Exclusion Criteria:

Current evidence, or history within the last 7 days, of an influenza-like illness as defined by fever (>38°C) and two or more of the following symptoms: cough, sore throat, runny nose, sneezing, limb / joint pain, headache, vomiting / diarrhoea in the absence of a known cause, other than influenza.
Use of anti-inflammatory drugs including corticosteroids, chronic maintenance therapy with NSAIDs, anti-Tumor Necrosis Factor (anti-TNF) or anti-Interleukin-1 (anti-IL1) within 60 days prior to dosing.
Current evidence of ongoing or acute infection, history of repeated, chronic or opportunistic infections (e.g. recurrent folliculitis, other cutaneous infections or repeated pneumonia) or history of a serious bacterial infection within 6 months of randomisation.
History of malignancy or significant cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions.
History chronic granulomatous infections, such as of Mycobacterium tuberculosis or any other previous Mycobacterium infection.
Creatinine clearance less than 60ml/min
Screens positive of Hepatitis B surface antigen, Hepatitis C antibody or Human Immunodeficiency Virus (HIV)
History of a severe allergic reaction, anaphylaxis or immunodeficiency.
Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
A positive pre-study drug/alcohol screen.
History of regular alcohol consumption within 6 months of the study
The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
History of sensitivity to any of the study medications, or components thereof
Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
Pregnant females as determined by positive serum or urine hCG test at screening.
Lactating females.
Unwillingness or inability to follow the procedures outlined in the protocol.
Subject is mentally or legally incapacitated.
Subject has received a live attenuated vaccine(s) within 30 days of randomisation or will require vaccination with a live attenuated vaccine prior to the end of the study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	GSK Investigational Site	Alicante		Spain	03004
2	GSK Investigational Site	Alzira/Valencia		Spain	46600
3	GSK Investigational Site	Granada		Spain	18012
4	GSK Investigational Site	La Roca del Valles (Barcelona)		Spain	08430
5	GSK Investigational Site	Lleida		Spain	25198
6	GSK Investigational Site	Madrid		Spain	28034
7	GSK Investigational Site	Madrid		Spain	28046
8	GSK Investigational Site	Malaga		Spain	29010
9	GSK Investigational Site	Málaga		Spain	29010
10	GSK Investigational Site	Petrer, Alicante		Spain	03610
11	GSK Investigational Site	Santander		Spain	39008
12	GSK Investigational Site	Birmingham	Warwickshire	United Kingdom	B15 2TT
13	GSK Investigational Site	Cambridge		United Kingdom	CB2 2GG
14	GSK Investigational Site	Dundee		United Kingdom	DD1 9SY